SCOTTSDALE, Ariz., July 8 AZ-MedPredict-Report
SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a
global provider of pharmaceutical competitive intelligence and market
research, has published a new report providing critical strategic insight for
pharma and biotech companies with a stake in the market for Rheumatoid
Arthritis (RA) therapies.
In this report, entitled Thought Leader Insight & Analysis: Rheumatoid
Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress
in developing biological and small molecule regimens for the treatment of
early RA.
According to this report, the key change in practice occurring in the
treatment of RA is the push toward earlier diagnosis and treatment, which is
associated with more durable remission. New biomarkers and approaches to
cellular imaging in early disease are also being investigated.
"Our Panel sheds light on which companies are likely to be positioned to
capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In
addition, they offer predictions on how tocilizumab, certolizumab and
golimumab will compete with the established biologicals, and how the current
market leaders are positioning to defend their brands in the RA space. Their
discussion will provide essential strategic and competitive insight for anyone
with a stake in this market."
The report also addresses pain management in RA, provides a postmortem on
the rituximab non-renal lupus trial, and discusses the most meaningful
clinical developments related to the following mechanisms: Anti-TNF,
Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase,
JAK, Syk, PDE5, and more.
Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda
Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb,
Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab,
Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma,
Pfizer, Roche/Chugai, Roche/Genentech, Sanofi-Aventis/Regeneron, UCB, Vertex
and Wyeth/Trubion.
MedPredict conducted in-depth, primary interviews with leading
rheumatologists from North America and Europe to provide the basis for this
report.
This report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of
over 1,000 global physician thought leaders, including 40+ specialties in 30+
therapeutic categories. Based on primary interviews with these thought
leaders, MedPredict publishes periodic reports in each category to keep
clients up-to-date on emerging trends and competitive activity. The reports
include thought leader reactions to recent publications and medical
conferences, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict Market Research
